Mitolactol

Summary

Mitolactol (CHEMBL2104612) is a phase-3 clinical-stage small molecule; indicated across 1 condition including central nervous system neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 307.96 Da · C6H12Br2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104612
Name	Mitolactol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5284380
Molecular formula	C6H12Br2O4
Molecular weight	307.96
InChIKey	VFKZTMPDYBFSTM-GUCUJZIJSA-N

SMILES: C([C@H]([C@@H]([C@@H]([C@H](CBr)O)O)O)O)Br

IUPAC name: (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol

Also known as: Dibromdulcit, Elobromol, Mitolactol, NCI-C04795, NSC-104800, MITOLACTOL

Patent coverage: 9,111 distinct patent families (40,304 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
central nervous system neoplasm	3	MONDO:0006130	EFO:1000158

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002620	PHASE3	COMPLETED	Radiation Therapy in Treating Patients With Brain Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).